Gensia Pharmaceuticals Inc. (NASDAQ:GNSA) announced that itfiled a marketing authorization application (MAA) with theMedicines Control Agency (MCA) in the United Kingdom forArasine in patients undergoing coronary artery bypass graftsurgery. The San Diego company has also submitted MAAs toeach of the other 11 members of the European Community andto the five countries that are members of the European FreeTrade Association. In addition, Gensia plans to file a regulatorysubmission in Canada by the end of January. It filed a newdrug application (NDA) with the FDA in late December onArasine.
(c) 1997 American Health Consultants. All rights reserved.